GlassScriptPhysician profile
Dmitriy Yadgarov
NPI 1831395078
$3,596.40
in general payments reported to CMS, 2019-2025
22 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $335 · 2021: $405 · 2022: $390 · 2023: $315 · 2024: $1,136 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.93 |
| Education | $324.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $879.19 | 2020-2025 | Breztri, Airsupra, Fasenra |
| Philips North America LLC | $595.94 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Glaxosmithkline, LLC. | $337.08 | 2019-2025 | Benlysta, Nucala |
| Sunovion Pharmaceuticals INC. | $292.49 | 2019-2020 | |
| Harmony Biosciences LLC | $263.94 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $179.98 | 2023-2025 | Uptravi, Opsumit |
| Olympus America INC. | $144.45 | 2024 | Spin Vision Video Processor |
| Regeneron Pharmaceuticals, INC. | $133.75 | 2024 | Dupixent |
| Insmed, INC. | $126.58 | 2019-2022 | |
| Allergan, INC. | $124.33 | 2021 | |
| Advanced Respiratory, INC | $100.74 | 2020-2021 | |
| Electromed, INC. | $84.61 | 2023-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2024 | |
| Pfizer INC. | $63.09 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.16 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $30.81 | 2023 | |
| Mylan Specialty L.P. | $24.78 | 2019 | |
| Amgen INC. | $24.62 | 2025 | Tezspire |
| Abbott Laboratories | $24.07 | 2020 | |
| United Therapeutics Corporation | $20.73 | 2021 | |
| Itamar Medical INC | $20.05 | 2023 | Watchpatone |
| Genentech USA, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Yadgarov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.